17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cellular senescence in the lung across the age spectrum

      review-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cellular senescence results in cell cycle arrest with secretion of cytokines, chemokines, growth factors, and remodeling proteins (senescence-associated secretory phenotype; SASP) that have autocrine and paracrine effects on the tissue microenvironment. SASP can promote remodeling, inflammation, infectious susceptibility, angiogenesis, and proliferation, while hindering tissue repair and regeneration. While the role of senescence and the contributions of senescent cells are increasingly recognized in the context of aging and a variety of disease states, relatively less is known regarding the portfolio and influences of senescent cells in normal lung growth and aging per se or in the induction or progression of lung diseases across the age spectrum such as bronchopulmonary dysplasia, asthma, chronic obstructive pulmonary disease, or pulmonary fibrosis. In this review, we introduce concepts of cellular senescence, the mechanisms involved in the induction of senescence, and the SASP portfolio that are relevant to lung cells, presenting the potential contribution of senescent cells and SASP to inflammation, hypercontractility, and remodeling/fibrosis: aspects critical to a range of lung diseases. The potential to blunt lung disease by targeting senescent cells using a novel class of drugs (senolytics) is discussed. Potential areas for future research on cellular senescence in the lung are identified.

          Related collections

          Most cited references152

          • Record: found
          • Abstract: found
          • Article: found

          Aging, Cellular Senescence, and Cancer

          For most species, aging promotes a host of degenerative pathologies that are characterized by debilitating losses of tissue or cellular function. However, especially among vertebrates, aging also promotes hyperplastic pathologies, the most deadly of which is cancer. In contrast to the loss of function that characterizes degenerating cells and tissues, malignant (cancerous) cells must acquire new (albeit aberrant) functions that allow them to develop into a lethal tumor. This review discusses the idea that, despite seemingly opposite characteristics, the degenerative and hyperplastic pathologies of aging are at least partly linked by a common biological phenomenon: a cellular stress response known as cellular senescence. The senescence response is widely recognized as a potent tumor suppressive mechanism. However, recent evidence strengthens the idea that it also drives both degenerative and hyperplastic pathologies, most likely by promoting chronic inflammation. Thus, the senescence response may be the result of antagonistically pleiotropic gene action.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cellular senescence in aging and age-related disease: from mechanisms to therapy.

            Cellular senescence, a process that imposes permanent proliferative arrest on cells in response to various stressors, has emerged as a potentially important contributor to aging and age-related disease, and it is an attractive target for therapeutic exploitation. A wealth of information about senescence in cultured cells has been acquired over the past half century; however, senescence in living organisms is poorly understood, largely because of technical limitations relating to the identification and characterization of senescent cells in tissues and organs. Furthermore, newly recognized beneficial signaling functions of senescence suggest that indiscriminately targeting senescent cells or modulating their secretome for anti-aging therapy may have negative consequences. Here we discuss current progress and challenges in understanding the stressors that induce senescence in vivo, the cell types that are prone to senesce, and the autocrine and paracrine properties of senescent cells in the contexts of aging and age-related diseases as well as disease therapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

              The healthspan of mice is enhanced by killing senescent cells using a transgenic suicide gene. Achieving the same using small molecules would have a tremendous impact on quality of life and the burden of age-related chronic diseases. Here, we describe the rationale for identification and validation of a new class of drugs termed senolytics, which selectively kill senescent cells. By transcript analysis, we discovered increased expression of pro-survival networks in senescent cells, consistent with their established resistance to apoptosis. Using siRNA to silence expression of key nodes of this network, including ephrins (EFNB1 or 3), PI3Kδ, p21, BCL-xL, or plasminogen-activated inhibitor-2, killed senescent cells, but not proliferating or quiescent, differentiated cells. Drugs targeting these same factors selectively killed senescent cells. Dasatinib eliminated senescent human fat cell progenitors, while quercetin was more effective against senescent human endothelial cells and mouse BM-MSCs. The combination of dasatinib and quercetin was effective in eliminating senescent MEFs. In vivo, this combination reduced senescent cell burden in chronologically aged, radiation-exposed, and progeroid Ercc1 −/Δ mice. In old mice, cardiac function and carotid vascular reactivity were improved 5 days after a single dose. Following irradiation of one limb in mice, a single dose led to improved exercise capacity for at least 7 months following drug treatment. Periodic drug administration extended healthspan in Ercc1 −/Δ mice, delaying age-related symptoms and pathology, osteoporosis, and loss of intervertebral disk proteoglycans. These results demonstrate the feasibility of selectively ablating senescent cells and the efficacy of senolytics for alleviating symptoms of frailty and extending healthspan.
                Bookmark

                Author and article information

                Journal
                Am J Physiol Lung Cell Mol Physiol
                Am. J. Physiol. Lung Cell Mol. Physiol
                ajplung
                Am J Physiol Lung Cell Mol Physiol
                AJPLUNG
                American Journal of Physiology - Lung Cellular and Molecular Physiology
                American Physiological Society (Bethesda, MD )
                1040-0605
                1522-1504
                1 May 2019
                20 February 2019
                1 May 2020
                : 316
                : 5
                : L826-L842
                Affiliations
                [1] 1Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Mayo Clinic , Rochester, Minnesota
                [2] 2Department of Anesthesiology and Perioperative Medicine, Mayo Clinic , Rochester, Minnesota
                [3] 3Department of Physiology and Biomedical Engineering, Mayo Clinic , Rochester, Minnesota
                [4] 4Center for Perinatal Research, The Research Institute at Nationwide Children’s Hospital , Columbus, Ohio
                [5] 5Department of Pediatrics, The Ohio State University , Columbus, Ohio
                Author notes
                [*]

                P. Parikh and S. Wicher contributed equally to this work.

                Address for reprint requests and other correspondence: Y. S. Prakash, Mayo Clinic, 4-184 W Jos SMH, 200 First St., SW Rochester, MN 55905 (e-mail: prakash.ys@ 123456mayo.edu ).
                Author information
                https://orcid.org/0000-0002-0027-9545
                https://orcid.org/0000-0002-2968-224X
                Article
                PMC6589594 PMC6589594 6589594 L-00424-2018 L-00424-2018
                10.1152/ajplung.00424.2018
                6589594
                30785345
                5007f7a7-eebd-40a2-9b8a-570e6e7d82a3
                Copyright © 2019 the American Physiological Society
                History
                : 18 September 2018
                : 14 February 2019
                : 14 February 2019
                Funding
                Funded by: Mayo Clinic 10.13039/100000871
                Funded by: HHS | National Institutes of Health (NIH) 10.13039/100000002
                Award ID: T32 HL105355
                Award ID: R00 HL131682
                Award ID: R01 HL138402
                Award ID: R01 HL056470
                Funded by: HHS | NIH | National Center for Advancing Translational Sciences (NCATS) 10.13039/100006108
                Award ID: UL1 TR002377
                Funded by: American Heart Association (AHA) 10.13039/100000968
                Award ID: 19POST34430017
                Categories
                Review
                Senescence in the Lung
                Custom metadata
                True

                airway,aging,senolytic,bronchi,alveoli
                airway, aging, senolytic, bronchi, alveoli

                Comments

                Comment on this article